1,814
Participants
Start Date
May 31, 2009
Primary Completion Date
June 30, 2013
Study Completion Date
June 30, 2013
Emtricitabine/tenofovir disoproxil fumarate
200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
Raltegravir
400 mg taken orally twice daily. An integrase inhibitor (INI).
Darunavir
800 mg taken orally once daily. A protease inhibitor (PI).
Ritonavir
100 mg taken orally once daily. A protease inhibitor (PI).
Atazanavir
300 mg taken orally once daily. A protease inhibitor (PI).
Cornell CRS, New York
NY Univ. HIV/AIDS CRS, New York
Metropolitan Hospital, New York
HIV Prevention & Treatment CRS, New York
Bronx-Lebanon Hosp. Ctr. CRS, The Bronx
SUNY Stony Brook NICHD CRS (5040), Stony Brook
AIDS Care CRS, Rochester
Univ. of Rochester ACTG CRS, Rochester
Pitt CRS, Pittsburgh
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia
Georgetown University CRS (GU CRS), Washington D.C.
Howard Univ. Washington DC NICHD CRS, Washington D.C.
IHV Baltimore Treatment CRS, Baltimore
Johns Hopkins Adult AIDS CRS, Baltimore
Virginia Commonwealth Univ. Medical Ctr. CRS, Richmond
Regional Center for Infectious Disease, Wendover Medical Center CRS (3203), Greensboro
Unc Aids Crs, Chapel Hill
Duke Univ. Med. Ctr. Adult CRS, Durham
The Ponce de Leon Center CRS, Atlanta
University of Florida Jacksonville (5051), Jacksonville
Univ. of Miami AIDS CRS, Miami
South Florida Childrens Diagnostic & Treatment Cen (5055), Fort Lauderdale
Vanderbilt Therapeutics CRS, Nashville
The Ohio State Univ. AIDS CRS, Columbus
Case CRS, Cleveland
Metro Health CRS, Cleveland
Univ. of Cincinnati CRS, Cincinnati
Wayne State Univ. CRS, Detroit
Henry Ford Hosp. CRS, Detroit
Northwestern University CRS, Chicago
Rush Univ. Med. Ctr. ACTG CRS, Chicago
Washington U CRS, St Louis
Tulane University New Orleans NICHD CRS (5095), New Orleans
Trinity Health and Wellness Center, Dallas
Houston AIDS Research Team CRS, Houston
University of Colorado Hospital CRS, Aurora
Denver Public Health CRS, Denver
USC CRS, Los Angeles
UCLA CARE Center CRS, Los Angeles
Harbor-UCLA Med. Ctr. CRS, Torrance
Miller Children's Hospital, Long Beach
Ucsd, Avrc Crs, San Diego
Ucsf Aids Crs, San Francisco
Stanford CRS, Palo Alto
The Research & Education Group- Portland CRS (31474), Portland
University of Washington AIDS CRS, Seattle
Alabama Therapeutics CRS, Birmingham
Massachusetts General Hospital CRS, Boston
Brigham and Women's Hosp. ACTG CRS, Boston
Bmc Actg Crs, Boston
Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston
Cooper Univ. Hosp. CRS, Camden
New Jersey Medical School- Adult Clinical Research Ctr. CRS, Newark
The Miriam Hosp. ACTG CRS, Providence
St. Jude/UTHSC CRS, Memphis
San Juan City Hosp. PR NICHD CRS, Rio Piedras
Puerto Rico-AIDS CRS, San Juan
Collaborators (2)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Bristol-Myers Squibb
INDUSTRY
Gilead Sciences
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
INDUSTRY
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK